Efficacy of nepafenac ophthalmic suspension 0.1% in improving clinical outcomes following cataract surgery in patients with diabetes: an analysis of two randomized studies

Rishi P Singh,1 Giovanni Staurenghi,2 Ayala Pollack,3 Adeniyi Adewale,4 Thomas M Walker,4 Dana Sager,4 Robert Lehmann5 1Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USA; 2Department of Biomedical and Clinical Science Luigi Sacco, Luigi Sacco Hospital, University of Milan, Milan,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Singh RP, Staurenghi G, Pollack A, Adewale A, Walker TM, Sager D, Lehmann R
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://doaj.org/article/ae0d48e6f07548058bf0857a31b3d582
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:ae0d48e6f07548058bf0857a31b3d582
record_format dspace
spelling oai:doaj.org-article:ae0d48e6f07548058bf0857a31b3d5822021-12-02T06:57:27ZEfficacy of nepafenac ophthalmic suspension 0.1% in improving clinical outcomes following cataract surgery in patients with diabetes: an analysis of two randomized studies1177-5483https://doaj.org/article/ae0d48e6f07548058bf0857a31b3d5822017-05-01T00:00:00Zhttps://www.dovepress.com/efficacy-of-nepafenac-ophthalmic-suspension-01-in-improving-clinical-o-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Rishi P Singh,1 Giovanni Staurenghi,2 Ayala Pollack,3 Adeniyi Adewale,4 Thomas M Walker,4 Dana Sager,4 Robert Lehmann5 1Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USA; 2Department of Biomedical and Clinical Science Luigi Sacco, Luigi Sacco Hospital, University of Milan, Milan, Italy; 3Ophthalmology Department, Kaplan Medical Center, Rehovot, Israel; 4Alcon Research Ltd., Fort Worth, TX, 5Lehmann Eye Center, Nacogdoches, TX, USA Objective: To assess the efficacy of nepafenac 0.1% ophthalmic suspension in improving the clinical outcomes following cataract surgery (CS) in patients with nonproliferative diabetic retinopathy. Methods: In two similar multicenter, randomized studies, patients received either nepafenac 0.1% or vehicle, instilled three times daily starting a day prior to surgery and continuing for 90 days postoperatively. A post hoc analysis of these two studies was conducted to assess 1) the likelihood for development of postoperative macular edema (ME), based on the percentage of patients who developed ME (≥30% increase from preoperative baseline in central subfield macular thickness) within 90 days following CS and 2) best-corrected visual acuity (BCVA) endpoints, including the percentage of patients with a BCVA improvement of ≥15 letters from preoperative baseline to Day 14 and maintained through Day 90. Results for individual studies and their pooled estimates (only visual acuity endpoints) are reported. Primary inference was based on odds ratio (OR). Results: This post hoc analysis included 411 patients (nepafenac 0.1%: 205; vehicle: 206). The incidence of postoperative ME within 90 days of CS was notably lower in the nepafenac-treated patients than in vehicle-treated patients (study 1: 3.2% vs 16.7%; OR =0.2, 95% confidence interval [CI] =0.1, 0.5, P=0.001; study 2: 5.0% vs 17.5%; OR =0.2, 95% CI =0.1, 0.8, P=0.018). A higher percentage of nepafenac-treated patients than vehicle-treated patients gained ≥15 letters from preoperative baseline to Day 14, which was maintained through Day 90 (study 1: 38.4% vs 21.4%; OR =2.4, 95% CI =1.4, 4.2, P=0.003; study 2: 35.0% vs 25.0%; OR =1.6, 95% CI =0.8, 3.2, P=0.172; pooled: 37.1% vs 22.8%; OR =2.0, 95% CI =1.3, 3.1, P=0.001). The odds of >5-letter and >10-letter loss in BCVA from postoperative Day 7 were higher in vehicle-treated than in nepafenac-treated patients. Conclusion: These results support the clinical benefit of prophylactic use of nepafenac 0.1% for reducing the risk of postoperative ME and for improvement in BCVA outcomes following CS in patients with nonproliferative diabetic retinopathy. Keywords: cataract surgery, nonproliferative diabetic retinopathy, nepafenac 0.1%, postoperative macular edema, visual outcomesSingh RPStaurenghi GPollack AAdewale AWalker TMSager DLehmann RDove Medical Pressarticlecataract surgerynon-proliferative diabetic retinopathynepafenac 0.1%postoperative macular edemavisual outcomesOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 1021-1029 (2017)
institution DOAJ
collection DOAJ
language EN
topic cataract surgery
non-proliferative diabetic retinopathy
nepafenac 0.1%
postoperative macular edema
visual outcomes
Ophthalmology
RE1-994
spellingShingle cataract surgery
non-proliferative diabetic retinopathy
nepafenac 0.1%
postoperative macular edema
visual outcomes
Ophthalmology
RE1-994
Singh RP
Staurenghi G
Pollack A
Adewale A
Walker TM
Sager D
Lehmann R
Efficacy of nepafenac ophthalmic suspension 0.1% in improving clinical outcomes following cataract surgery in patients with diabetes: an analysis of two randomized studies
description Rishi P Singh,1 Giovanni Staurenghi,2 Ayala Pollack,3 Adeniyi Adewale,4 Thomas M Walker,4 Dana Sager,4 Robert Lehmann5 1Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USA; 2Department of Biomedical and Clinical Science Luigi Sacco, Luigi Sacco Hospital, University of Milan, Milan, Italy; 3Ophthalmology Department, Kaplan Medical Center, Rehovot, Israel; 4Alcon Research Ltd., Fort Worth, TX, 5Lehmann Eye Center, Nacogdoches, TX, USA Objective: To assess the efficacy of nepafenac 0.1% ophthalmic suspension in improving the clinical outcomes following cataract surgery (CS) in patients with nonproliferative diabetic retinopathy. Methods: In two similar multicenter, randomized studies, patients received either nepafenac 0.1% or vehicle, instilled three times daily starting a day prior to surgery and continuing for 90 days postoperatively. A post hoc analysis of these two studies was conducted to assess 1) the likelihood for development of postoperative macular edema (ME), based on the percentage of patients who developed ME (≥30% increase from preoperative baseline in central subfield macular thickness) within 90 days following CS and 2) best-corrected visual acuity (BCVA) endpoints, including the percentage of patients with a BCVA improvement of ≥15 letters from preoperative baseline to Day 14 and maintained through Day 90. Results for individual studies and their pooled estimates (only visual acuity endpoints) are reported. Primary inference was based on odds ratio (OR). Results: This post hoc analysis included 411 patients (nepafenac 0.1%: 205; vehicle: 206). The incidence of postoperative ME within 90 days of CS was notably lower in the nepafenac-treated patients than in vehicle-treated patients (study 1: 3.2% vs 16.7%; OR =0.2, 95% confidence interval [CI] =0.1, 0.5, P=0.001; study 2: 5.0% vs 17.5%; OR =0.2, 95% CI =0.1, 0.8, P=0.018). A higher percentage of nepafenac-treated patients than vehicle-treated patients gained ≥15 letters from preoperative baseline to Day 14, which was maintained through Day 90 (study 1: 38.4% vs 21.4%; OR =2.4, 95% CI =1.4, 4.2, P=0.003; study 2: 35.0% vs 25.0%; OR =1.6, 95% CI =0.8, 3.2, P=0.172; pooled: 37.1% vs 22.8%; OR =2.0, 95% CI =1.3, 3.1, P=0.001). The odds of >5-letter and >10-letter loss in BCVA from postoperative Day 7 were higher in vehicle-treated than in nepafenac-treated patients. Conclusion: These results support the clinical benefit of prophylactic use of nepafenac 0.1% for reducing the risk of postoperative ME and for improvement in BCVA outcomes following CS in patients with nonproliferative diabetic retinopathy. Keywords: cataract surgery, nonproliferative diabetic retinopathy, nepafenac 0.1%, postoperative macular edema, visual outcomes
format article
author Singh RP
Staurenghi G
Pollack A
Adewale A
Walker TM
Sager D
Lehmann R
author_facet Singh RP
Staurenghi G
Pollack A
Adewale A
Walker TM
Sager D
Lehmann R
author_sort Singh RP
title Efficacy of nepafenac ophthalmic suspension 0.1% in improving clinical outcomes following cataract surgery in patients with diabetes: an analysis of two randomized studies
title_short Efficacy of nepafenac ophthalmic suspension 0.1% in improving clinical outcomes following cataract surgery in patients with diabetes: an analysis of two randomized studies
title_full Efficacy of nepafenac ophthalmic suspension 0.1% in improving clinical outcomes following cataract surgery in patients with diabetes: an analysis of two randomized studies
title_fullStr Efficacy of nepafenac ophthalmic suspension 0.1% in improving clinical outcomes following cataract surgery in patients with diabetes: an analysis of two randomized studies
title_full_unstemmed Efficacy of nepafenac ophthalmic suspension 0.1% in improving clinical outcomes following cataract surgery in patients with diabetes: an analysis of two randomized studies
title_sort efficacy of nepafenac ophthalmic suspension 0.1% in improving clinical outcomes following cataract surgery in patients with diabetes: an analysis of two randomized studies
publisher Dove Medical Press
publishDate 2017
url https://doaj.org/article/ae0d48e6f07548058bf0857a31b3d582
work_keys_str_mv AT singhrp efficacyofnepafenacophthalmicsuspension01inimprovingclinicaloutcomesfollowingcataractsurgeryinpatientswithdiabetesananalysisoftworandomizedstudies
AT staurenghig efficacyofnepafenacophthalmicsuspension01inimprovingclinicaloutcomesfollowingcataractsurgeryinpatientswithdiabetesananalysisoftworandomizedstudies
AT pollacka efficacyofnepafenacophthalmicsuspension01inimprovingclinicaloutcomesfollowingcataractsurgeryinpatientswithdiabetesananalysisoftworandomizedstudies
AT adewalea efficacyofnepafenacophthalmicsuspension01inimprovingclinicaloutcomesfollowingcataractsurgeryinpatientswithdiabetesananalysisoftworandomizedstudies
AT walkertm efficacyofnepafenacophthalmicsuspension01inimprovingclinicaloutcomesfollowingcataractsurgeryinpatientswithdiabetesananalysisoftworandomizedstudies
AT sagerd efficacyofnepafenacophthalmicsuspension01inimprovingclinicaloutcomesfollowingcataractsurgeryinpatientswithdiabetesananalysisoftworandomizedstudies
AT lehmannr efficacyofnepafenacophthalmicsuspension01inimprovingclinicaloutcomesfollowingcataractsurgeryinpatientswithdiabetesananalysisoftworandomizedstudies
_version_ 1718399655009583104